ReviewTherapeutic advances in medical oncology2026
Closing the evidence gap in older adults with extensive-stage small-cell lung cancer: a CGA-guided, risk-adapted treatment framework.
Review in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic decision-making for older adults, operationally defined in this review as patients aged ⩾65 years, with extensive-stage small-cell lung cancer (ES-SCLC) remains clinically challenging, complicated by heterogeneous decline in physiological reserve, multiple comorbidities, and narrow therapeutic indices. Although chemoimmunotherapy has redefined the first-line standard of care, the selection bias inherent in pivotal registrational randomized controlled trials-which often exclude the oldest-old and frail patients-limits the generalizability of their efficacy and safety profiles within complex real-world populations. As the therapeutic armamentarium expands, emerging modalities such as small-molecule anti-angiogenic agents, hypofractionated or adaptive radiotherapy, and novel molecular therapies (e.g., lurbinectedin and delta-like ligand 3-targeting constructs) offer tailored therapeutic avenues for this demographic. However, a pronounced evidence gap persists regarding geriatric-specific toxicity and functional endpoints within the existing evidence hierarchy. Consequently, the integration of Comprehensive Geriatric Assessment (CGA) for functional status stratification is imperative to navigate current therapeutic bottlenecks. The objective of this narrative review is to summarize recent therapeutic advances in older adults with ES-SCLC, critically examine the limitations of current evidence, and propose a CGA-guided framework for risk-adapted clinical decision-making and holistic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.